{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:51:57Z","timestamp":1787791917315,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,30]]},"DOI":"10.7759\/cureus.74820","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T11:52:52Z","timestamp":1732967572000},"source":"Crossref","is-referenced-by-count":3,"title":["Clinical Profile, Comorbidities and Therapies in Type 2 Diabetes Patients on Sitagliptin-Based Therapy in Indian Outpatient Setting"],"prefix":"10.7759","author":[{"given":"Khurshid A","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran P","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanumantha Rao","family":"Maddukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S N","family":"Routray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Kinare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Mate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R V","family":"Lokesh Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"IDF Diabetes Atlas","author":"Federation ID","year":"2021","unstructured":"Federation ID, 10th Edition. IDF Diabetes Atlas. International Diabetes Federation, 2021."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1627_21","article-title":"Epidemiology of type 2 diabetes in India","volume":"69","author":"Pradeepa R","year":"2021","unstructured":"Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021, 69:2932-38. 10.4103\/ijo.IJO_1627_21","journal-title":"Indian J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1168291","article-title":"Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus","volume":"32","author":"Iglay K","year":"2016","unstructured":"Iglay K, Hannachi H, Joseph Howie P, et al.. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016, 32:1243-52. 10.1185\/03007995.2016.1168291","journal-title":"Curr Med Res Opin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.105","article-title":"Recent updates to clinical practice guidelines for diabetes mellitus","volume":"37","author":"Yu J","year":"2022","unstructured":"Yu J, Lee SH, Kim MK. Recent updates to clinical practice guidelines for diabetes mellitus. Endocrinol Metab (Seoul). 2022, 37:26-37. 10.3803\/EnM.2022.105","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/950571","article-title":"Sitagliptin: is it effective in routine clinical practice?","volume":"2015","author":"Mohan Dallumal R","year":"2015","unstructured":"Mohan Dallumal R, Chua SS, Wu DB, Vethakkan SR. Sitagliptin: is it effective in routine clinical practice?. Int J Endocrinol. 2015, 2015:950571. 10.1155\/2015\/950571","journal-title":"Int J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0169-1","article-title":"Sitagliptin: a review of its use in patients with type 2 diabetes mellitus","volume":"74","author":"Plosker GL","year":"2014","unstructured":"Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014, 74:223-42. 10.1007\/s40265-013-0169-1","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27103055","article-title":"Role of dipeptidyl peptidase 4 inhibitors in antidiabetic treatment","volume":"27","author":"Yin R","year":"2022","unstructured":"Yin R, Xu Y, Wang X, Yang L, Zhao D. Role of dipeptidyl peptidase 4 inhibitors in antidiabetic treatment. Molecules. 2022, 27:3055. 10.3390\/molecules27103055","journal-title":"Molecules"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16152720","article-title":"The role of dpp-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect","volume":"16","author":"Makrilakis K","year":"2019","unstructured":"Makrilakis K. The role of dpp-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. Int J Environ Res Public Health. 2019, 16:10.3390\/ijerph16152720","journal-title":"Int J Environ Res Public Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-27301-9","article-title":"Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study","volume":"13","author":"Nagao M","year":"2023","unstructured":"Nagao M, Sasaki J, Sugihara H, Tanimura-Inagaki K, Harada T, Sakuma I, Oikawa S. Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. Sci Rep. 2023, 13:134. 10.1038\/s41598-022-27301-9","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01204.x","article-title":"Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes","volume":"12","author":"Williams-Herman D","year":"2010","unstructured":"Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010, 12:442-51. 10.1111\/j.1463-1326.2010.01204.x","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129477","article-title":"Four-year durability of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes in clinical practice; cosmic study","volume":"10","author":"Ku EJ","year":"2015","unstructured":"Ku EJ, Jung KY, Kim YJ, et al.. Four-year durability of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes in clinical practice; cosmic study. PLoS One. 2015, 10:e0129477. 10.1371\/journal.pone.0129477","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12432","article-title":"Efficacy and safety of sitagliptin\/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study","volume":"9","author":"Kim SS","year":"2017","unstructured":"Kim SS, Kim IJ, Lee KJ, et al.. Efficacy and safety of sitagliptin\/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. J Diabetes. 2017, 9:412-22. 10.1111\/1753-0407.12432","journal-title":"J Diabetes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel B","year":"2006","unstructured":"Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006, 29:2638-43. 10.2337\/dc06-0706","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02353.x","article-title":"Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study","volume":"64","author":"Seck T","year":"2010","unstructured":"Seck T, Nauck M, Sheng D, et al.. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010, 64:562-76. 10.1111\/j.1742-1241.2010.02353.x","journal-title":"Int J Clin Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01334.x","article-title":"Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial","volume":"13","author":"Arechavaleta R","year":"2011","unstructured":"Arechavaleta R, Seck T, Chen Y, et al.. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011, 13:160-8. 10.1111\/j.1463-1326.2010.01334.x","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S93076","article-title":"Sitagliptin\/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy","volume":"10","author":"Hayes J","year":"2016","unstructured":"Hayes J, Anderson R, Stephens JW. Sitagliptin\/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Drug Des Devel Ther. 2016, 10:2263-70. 10.2147\/DDDT.S93076","journal-title":"Drug Des Devel Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour SA","year":"2014","unstructured":"Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014, 37:740-50. 10.2337\/dc13-0467","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46767","article-title":"The real dapsi: a real-world retrospective study on assessing the efficacy and safety of a fixed-dose combination of dapagliflozin and sitagliptin in the Indian population","volume":"15","author":"Bhattacharjee R","year":"2023","unstructured":"Bhattacharjee R, Rai M, Joshi P, Prasad A, Birla A. The real dapsi: a real-world retrospective study on assessing the efficacy and safety of a fixed-dose combination of dapagliflozin and sitagliptin in the Indian population. Cureus. 2023, 15:e46767. 10.7759\/cureus.46767","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02523-z","article-title":"Fixed-dose combination of dapagliflozin\u2009+\u2009sitagliptin\u2009+\u2009metformin in patients with type 2 diabetes poorly controlled with metformin: phase 3, randomized comparison with dual combinations","volume":"40","author":"Sahay RK","year":"2023","unstructured":"Sahay RK, Giri R, Shembalkar JV, et al.. Fixed-dose combination of dapagliflozin\u2009+\u2009sitagliptin\u2009+\u2009metformin in patients with type 2 diabetes poorly controlled with metformin: phase 3, randomized comparison with dual combinations. Adv Ther. 2023, 40:3227-46. 10.1007\/s12325-023-02523-z","journal-title":"Adv Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-024-01321-9","article-title":"A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial","volume":"44","author":"Singh AK","year":"2024","unstructured":"Singh AK, Sahay R, Gil N, et al.. A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial. Int J Diabetes Dev Ctries. 2024, 44:67-76. 10.1007\/s13410-024-01321-9","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2019.12.006","article-title":"Prevalence of comorbidities in patients with type-2 diabetes mellitus","volume":"14","author":"Ak\u0131n S","year":"2020","unstructured":"Ak\u0131n S, B\u00f6l\u00fck C. Prevalence of comorbidities in patients with type-2 diabetes mellitus. Prim Care Diabetes. 2020, 14:431-34. 10.1016\/j.pcd.2019.12.006","journal-title":"Prim Care Diabetes"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2820w","article-title":"Primary care-based investigation of the effect of sitagliptin on blood pressure in hypertensive patients with type 2 diabetes","volume":"9","author":"Yuasa S","year":"2017","unstructured":"Yuasa S, Sato K, Furuki T, et al.. Primary care-based investigation of the effect of sitagliptin on blood pressure in hypertensive patients with type 2 diabetes. J Clin Med Res. 2017, 9:188-92. 10.14740\/jocmr2820w","journal-title":"J Clin Med Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5551\/jat.41343","article-title":"Effects of a dipeptidyl peptidase 4 inhibitor sitagliptin on glycemic control and lipoprotein metabolism in patients with type 2 diabetes mellitus (GLORIA trial)","volume":"25","author":"Masuda D","year":"2018","unstructured":"Masuda D, Kobayashi T, Sairyou M, et al.. Effects of a dipeptidyl peptidase 4 inhibitor sitagliptin on glycemic control and lipoprotein metabolism in patients with type 2 diabetes mellitus (GLORIA trial). J Atheroscler Thromb. 2018, 25:512-20. 10.5551\/jat.41343","journal-title":"J Atheroscler Thromb"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/jrms.JRMS_78_20","article-title":"Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin","volume":"26","author":"Narimani R","year":"2021","unstructured":"Narimani R, Kachuei A, Rezvanian H, Feizi A, Poorpoone M. Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin. J Res Med Sci. 2021, 26:35. 10.4103\/jrms.JRMS_78_20","journal-title":"J Res Med Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/305782-clinical-profile-comorbidities-and-therapies-in-type-2-diabetes-patients-on-sitagliptin-based-therapy-in-indian-outpatient-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T11:52:54Z","timestamp":1732967574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/305782-clinical-profile-comorbidities-and-therapies-in-type-2-diabetes-patients-on-sitagliptin-based-therapy-in-indian-outpatient-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.74820","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,30]]}}}